Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 9/20 | 0.62 |
| ▸ | FPR2 | P25090 | 7/20 | 0.62 |
| ▸ | IDO1 | P14902 | 6/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11028972 | 1.00 | GRM5 (0.62) | GRM5FPR2IDO1L3MBTL1NPC1 | |
| SCHEMBL9960986 | 1.00 | GRM5 (0.62) | GRM5FPR2IDO1L3MBTL1NPC1 | |
| SCHEMBL11028190 | 0.85 | GRM5 (0.59) | GRM5FPR2IDO1NPC1RAB9A | |
| SCHEMBL9953339 | 0.85 | GRM5 (0.59) | GRM5FPR2IDO1NPC1RAB9A | |
| SCHEMBL11028775 | 0.85 | GRM5 (0.59) | GRM5FPR2IDO1NPC1RAB9A | |
| SCHEMBL11030975 | 0.85 | FPR2 (0.69) | GRM5FPR2NPC1RAB9A | |
| SCHEMBL11031602 | 0.85 | FPR2 (0.69) | GRM5FPR2NPC1RAB9A | |
| SCHEMBL11031433 | 0.85 | FPR2 (0.69) | GRM5FPR2NPC1RAB9A | |
| SCHEMBL11028395 | 0.84 | GRM5 (0.50) | GRM5FPR2L3MBTL1 | |
| SCHEMBL19192050 | 0.84 | GRM5 (0.70) | GRM5FPR2IDO1L3MBTL1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3263566-A1 | BICYCLO[3.2.1]OCTYL AMIDE DERIVATIVES AS ALLOSTERIC MODULATORS OF THE METABOTROPIC GLUTAMATE RECEPTOR 5 (MGLU5 OR MGLUR5) FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM (CNS) DISORDERS | H. Lundbeck A/S (DK) | 2018-01-03 | — | — | EP | claimed |
| US-9656975-B2 | Bicyclo[3.2.1]octyl amide derivatives and uses of same | H. LUNDBECK A/S (DK) | 2017-05-23 | — | — | US | claimed |
| US-20150057289-A1 | BICYCLO[3.2.1.]OCTYL AMIDE DERIVATIVES AND USES OF SAME | H. LUNDBECK A/S (DK) | 2015-02-26 | — | — | US | claimed |
| US-8921370-B2 | Bicyclo[3.2.1]octyl amide derivatives and uses of same | H. LUNDBECK A/S (DK) | 2014-12-30 | — | — | US | claimed |
| EP-3263566-A1 | BICYCLO[3.2.1]OCTYL AMIDE DERIVATIVES AS ALLOSTERIC MODULATORS OF THE METABOTROPIC GLUTAMATE RECEPTOR 5 (MGLU5 OR MGLUR5) FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM (CNS) DISORDERS | H. Lundbeck A/S (DK) | 2018-01-03 | — | — | EP | disclosed |
| US-20170217950-A1 | Bicyclo[3.2.1]Octyl Amide Derivatives and Uses of Same | H. LUNDBECK A/S (DK) | 2017-08-03 | — | — | US | disclosed |
| EP-2654422-B1 | Bicyclo[3.2.1]octyl amide derivatives as allosteric modulators of the metabotropic glutamate receptor 5 (mGlu5 or mGluR5) for the treatment of central nervous system (CNS) disorders | H LUNDBECK AS (DK) | 2017-08-02 | — | — | EP | disclosed |
| US-9656975-B2 | Bicyclo[3.2.1]octyl amide derivatives and uses of same | H. LUNDBECK A/S (DK) | 2017-05-23 | — | — | US | disclosed |
| US-20150057289-A1 | BICYCLO[3.2.1.]OCTYL AMIDE DERIVATIVES AND USES OF SAME | H. LUNDBECK A/S (DK) | 2015-02-26 | — | — | US | disclosed |
| US-8921370-B2 | Bicyclo[3.2.1]octyl amide derivatives and uses of same | H. LUNDBECK A/S (DK) | 2014-12-30 | — | — | US | disclosed |
| US-20120190686-A1 | BICYCLO[3.2.1]OCTYL AMIDE DERIVATIVES AND USES OF SAME | H. LUNDBECK A/S (DK) | 2012-07-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170217950-A1 | Bicyclo[3.2.1]Octyl Amide Derivatives and Uses of Same | SLC10A1, CLIC1, ABCB11 | GRM5 3148/4885FPR2 2633/4885IDO1 1609/4885 |
| US-20150057289-A1 | BICYCLO[3.2.1.]OCTYL AMIDE DERIVATIVES AND USES OF SAME | SLC10A1, CLIC1, ABCB11 | GRM5 3192/4885FPR2 2583/4885IDO1 1621/4885 |
| US-20120190686-A1 | BICYCLO[3.2.1]OCTYL AMIDE DERIVATIVES AND USES OF SAME | SLC10A1, CLIC1, ABCB11 | GRM5 3148/4885FPR2 2633/4885IDO1 1609/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.